CETP inhibitors trials

6 studies from 2007 to 2026, with 76,363 people taking part. Results: 1 fewer heart events or deaths, 3 no clear benefit, 2 lipid or plaque goal met. Every summary comes from the trial's PubMed abstract.

All 6 studies

• BROOKLYN2026 · Obicetrapib · 354 people

  In patients with heterozygous familial hypercholesterolemia already on maximally tolerated lipid-lowering therapy, adding obicetrapib substantially lowered LDL cholesterol (and improved other lipid parameters) compared with placebo and was well tolerated.

  Primary lipid endpoint metCETP inhibitorsInvestigational

• BROADWAY2025 · Obicetrapib · 2,530 people

  In high-risk patients already on maximum tolerated lipid-lowering therapy, adding obicetrapib 10 mg daily lowered LDL cholesterol by about 30% more than placebo with a similar rate of adverse events.

  Primary lipid endpoint metCETP inhibitorsInvestigational

• ACCELERATE2017 · Evacetrapib · 12,092 people

  Despite markedly improving LDL and HDL cholesterol levels, evacetrapib did not reduce cardiovascular events compared with placebo in high-risk vascular disease patients, and the trial was stopped early for futility.

  No significant benefitCETP inhibitorsDiscontinued

• REVEAL2017 · Anacetrapib · 30,449 people

  Adding the CETP inhibitor anacetrapib to intensive statin therapy modestly reduced major coronary events in patients with atherosclerotic vascular disease, without significant safety concerns.

  BenefitCETP inhibitorsNot marketed

• dal-OUTCOMES2012 · Dalcetrapib · 15,871 people

  In patients with a recent acute coronary syndrome, dalcetrapib raised HDL cholesterol but did not reduce cardiovascular events or mortality compared with placebo.

  No significant benefitCETP inhibitorsNot approved

• ILLUMINATE2007 · Torcetrapib · 15,067 people

  Adding torcetrapib to atorvastatin raised HDL and lowered LDL but increased cardiovascular events and overall death, so the trial was stopped early and the drug should not be used.

  HarmCETP inhibitorsDiscontinued

Other medicines

• Statins
• Ezetimibe and bile acid binders
• Bempedoic acid
• PCSK9 inhibitors
• Lp(a) medicines
• Fibrates, omega-3 and niacin
• APOC3, ANGPTL3 and lomitapide
• Genetics and gene editing
• Meta-analyses

Search and filter all 106 studies in the trial database. Education only, not medical advice.